Reasons for failure include insufficient accumulation of mutated tumor antigens [112], limited cross-presentation due to suppressed migration of APCs from the tumor [113] or lack of necessary signals, such as CD40, which is delivered predominantly by CD4+ T-cells [114], and ineffective presentation of the lysed tumor cells used in the vaccine. Here, CD4 is linked to neoplasm.